scholarly journals Neonatal isolated ACTH deficiency (IAD): a potentially life-threatening but treatable cause of neonatal cholestasis: Table 1

2016 ◽  
pp. bcr2016215032 ◽  
Author(s):  
Mahdi Alsaleem ◽  
Lina Saadeh ◽  
Amrit Misra ◽  
Shailender Madani
2020 ◽  
Vol 6 (6) ◽  
pp. e338-e341
Author(s):  
Fatimah Mohammed Alabdrabalnabi ◽  
Zahra Abdulwahed AL Saeed ◽  
Yasir Abuelgasim Elamin

Objective: Isolated adrenocorticotropic hormone (ACTH) deficiency is characterized by loss of adrenocorticotropic hormone, resulting in adrenal insufficiency, which can lead to life threatening severe hypoglycemia. We report a case of isolated ACTH deficiency with emphases on presentation, common etiologies, diagnosis, and management. Methods: The clinical course in addition to laboratory and imaging results are presented. These include cortisol level, ACTH, other pituitary hormones, insulin tolerance test, pituitary antibodies, and pituitary magnetic resonance imaging. Results: A 19-year-old male was brought by ambulance to the emergency department with loss of consciousness and a random blood sugar of 30 mg/dL. Our patient had a barely detectable level of plasma ACTH repeatedly and cortisol <1 μg/dL. There was no involvement of other pituitary hormones. Steroid replacement therapy led to resolution of all symptoms and prevented further episodes of hypoglycemia. Conclusion: Isolated ACTH deficiency is a rare condition that is challenging to diagnose and can lead to serious life-threatening problems if unrecognized. Proper management can be achieved with appropriate hydrocortisone supplementation to mimic the normal secretion under both normal conditions and during a state of stress.


1986 ◽  
Vol 113 (1_Suppl) ◽  
pp. S172
Author(s):  
H. TILLIL ◽  
H.-CH. BLOSSEY ◽  
G. HINTZE ◽  
J. KÖBBERLING

2013 ◽  
Author(s):  
Naoko Kumagai ◽  
Kazufumi Honda ◽  
Yohei Muroya ◽  
Masanori Shimodaira ◽  
Kaoru Tsuzawa ◽  
...  

2014 ◽  
Author(s):  
Michelle Mangual ◽  
Jose Hernan-Martinez ◽  
Monica Santiago ◽  
Carlos Figueroa ◽  
Rafael Trinidad ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Katsunori Manaka ◽  
Junichiro Sato ◽  
Maki Takeuchi ◽  
Kousuke Watanabe ◽  
Hidenori Kage ◽  
...  

AbstractImmune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adrenal insufficiency (AI) can be life-threatening especially in patients with delayed diagnosis. We retrospectively investigated secondary AI in ICI-treated patients. A total of 373 cancer patients treated with ICIs were included and evaluated. An adrenocorticotropic hormone (ACTH) deficiency was described in 13 patients. Among 24 patients with a combination of nivolumab and ipilimumab therapy, 7 patients (29%) developed secondary AI in a median time of 8 weeks during the combination therapy and 2 of 15 patients (13%) developed isolated ACTH deficiency during maintenance nivolumab monotherapy following the combination therapy. More than half of the patients (4/7) with a combination therapy-induced multiple anterior hormone deficiencies was diagnosed as secondary AI based on regular ACTH and cortisol tests with slight subjective symptoms. Secondary AI can arise frequently and rapidly in cancer patients receiving a combination ICI therapy, and thus we speculate active surveillance of AI using regular ACTH and cortisol tests during the combination therapy might be useful for avoiding life-threatening conditions due to secondary AI.


Sign in / Sign up

Export Citation Format

Share Document